IQIRVO

This brand name is authorized in United States

Active ingredients

The drug IQIRVO contains one active pharmaceutical ingredient (API):

1 Elafibranor UNII 2J3H5C81A5 - ELAFIBRANOR

Elafibranor and its main active metabolite GFT1007 are dual peroxisome proliferator-activated receptor (PPAR)α/δ agonists. PPAR α/δ are thought to be key regulators of bile acid (BA) homeostasis, inflammation and fibrosis. Activation of PPARα and PPARδ decreases bile toxicity and improve cholestasis by modulating BA synthesis, detoxification and transporters. Activation of PPARα and PPARδ also has anti-inflammatory effects by acting on different pathways. Read about Elafibranor

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
IQIRVO Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC
IQIRVO Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A05AX06		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy → A05AX Other drugs for bile therapy
Discover more medicines within A05AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 15054-0080